| NCT ID | NCT02871336 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Paoli-Calmettes |
| Condition | Pancreatic Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2014-11 |
| Primary Completion | 2030-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2014-11 with a primary completion date of 2030-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This data base has been set in order to gather medical and surgical information from patients who have undergone surgery for pancreatic cancer, at Institut Paoli Calmettes or Assistance Publique des Hôpitaux de Marseille, France.
Eligibility Criteria
Inclusion Criteria: * Patient \>18 ans * Surgery for a pancreatic cancer Exclusion Criteria: * Patient refusal to participate in the study
Contact & Investigator
Olivier Turrini, MD,PhD
PRINCIPAL INVESTIGATOR
Institut Paoli-Calmettes
Frequently Asked Questions
Who can join the NCT02871336 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02871336 currently recruiting?
Yes, NCT02871336 is actively recruiting participants. Contact the research team at drci.up@ipc.unicancer.fr for enrollment information.
Where is the NCT02871336 trial being conducted?
This trial is being conducted at Marseille, France.
Who is sponsoring the NCT02871336 clinical trial?
NCT02871336 is sponsored by Institut Paoli-Calmettes. The principal investigator is Olivier Turrini, MD,PhD at Institut Paoli-Calmettes. The trial plans to enroll 1,500 participants.